This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Org 50081
Description: Org 50081 inhibits serotonin receptors, with a high affinity for the 5-HT2 receptors. Org 50081 is the S-enantiomer of mirtazpine that is dextrorotatory (rotates plane-polarized light clockwise).
Deal Structure: Esmirtazapine was originally developed by Organon.
In November 2007, Schering-Plough announced that it completed the acquisition of Organon BioSciences N.V. Schering-Plough acquired Organon BioSciences from Akzo Nobel N.V. for approximately euro 11 billion in cash.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Merck & Co and Schering-Plough announced that their merger completed on November 3, 2009.
Additional information available to subscribers only: